On November 3, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that members of its executive team will participate in the following upcoming investor conferences (Press release, Aura Biosciences, NOV 3, 2022, View Source [SID1234623023]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stifel 2022 Healthcare Conference at the Lotte New York Palace on Wednesday, November 16, 2022.
Presentation at 10:55 a.m. ET.
5th Annual 2022 Evercore ISI HealthCONx on Tuesday, November 29, 2022.
Fireside chat at 8:25 a.m. ET.
A live webcast of the Stifel presentation and Evercore ISI fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcasts will be archived for 90 days following the presentation date.